Christopher K. Dyke - Concepedia

Author

Christopher K. Dyke

Also Known As

C K Dyke, C. K. Dyke, C.K. DYKE, C.K. Dyke, Christopher Dyke, Christopher K Dyke, Christopher K. Dyke, Christopher Kent Dyke, Robert Harrington

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

National Heart Lung and Blood Institute National Institutes of Health Duke Medical Center Duke University Clinical Research Institute

About

Christopher K. Dyke is an author at National Heart Lung and Blood Institute specializing in medicine, cardiovascular disease, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	700
2	Public Health	2	2	86
3	Engineering	1	1	16
4	Health Sciences	1	1	53
5	Anesthesia	1	1	53

Christopher K. Dyke

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Prognosis of Negative Adenosine Stress Magnetic Resonance in Patients Presenting to an Emergency Department With Chest Pain W. Patricia Ingkanisorn, Raymond Y. Kwong, Nicole S. Bohme, Journal of the American College of Cardiology Chest InjuryChest PainMedicineCardiologyEmergency Department	2006	313
Prevalence and Prognosis of Unrecognized Myocardial Infarction Determined by Cardiac Magnetic Resonance in Older Adults Erik B. Schelbert, Jie Cao, Sigurður Sigurdsson, JAMA	2012	281
First-in-Human Experience of an Antidote-Controlled Anticoagulant Using RNA Aptamer Technology Christopher K. Dyke, Steven R. Steinhubl, Neal S. Kleiman, Circulation	2006	218
Role of nitric oxide in exercise hyperaemia during prolonged rhythmic handgripping in humans. Christopher K. Dyke, David N. Proctor, Niki M. Dietz, The Journal of Physiology	1995	157
Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease Mark Y. Chan, Mauricio G. Cohen, Christopher K. Dyke, Circulation	2008	129
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy Michael A. Blazing, James A. de Lemos, Christopher K. Dyke, American Heart Journal ThrombosisCardiovascular DiseaseMedicineClinical TrialsCardiovascular Pharmacology	2001	90
Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic Yuchi Han, Tiffany Chen, Jennifer Bryant, Journal of Cardiovascular Magnetic Resonance	2020	87
Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the PARAGON-B trial Kenneth W. Mahaffey, Matthew T. Roe, Christopher K. Dyke, American Heart Journal ThrombosisCardiovascular DiseaseCoronary UnitCoronary Artery DiseaseClinical Epidemiology	2002	76
First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease Christopher K. Dyke, Richard C. Becker, Neal S. Kleiman, Circulation	2002	63
Effect of skeletal muscle fiber type on the pressor response evoked by static contraction in rabbits L. B. Wilson, Christopher K. Dyke, D. Parsons, Journal of Applied Physiology Muscle FunctionNeuromuscular BlockadeMuscle PhysiologyPhysiological ResearchKinesiology	1995	53

Page 1